Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Early digns of efficacy!!!!

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Jul 14, 2022 8:19am

111 Views

Post# 34823415

RE:RE:RE:Early digns of efficacy!!!!

Don't think that's right. They report prostate and endometrial. Endo has high sortilin for advanced cancers, prostate less so.

realitycheck4u wrote:
And it's working on colorectal cancer - which it normally would not work on. Interesting.

stockman75 wrote: Intersted to hear the medical experts on our boards input on this pr. I am confused a bit on what constitutes efficacy. I have been hearing 30% reduction in tumor size but isn't stabilizing a advanced\progressive disease a great result? Not to mention with less side effects? So in other words if a drug stops tumor growth with less side effects than current standard is that not a great result?